180 usd

Levitee Labs Completes Acquisition of Earth Circle Organics, Adds Superfoods Company to Portfolio

  • Acquisition adds 180+ SKUs across three brands to the Levitee portfolio: Earth Circle Organics, Earth Shift Products, and Ojio
  • Combined, the three brands generated over USD $2.0M in revenue in the past 12 months, with USD $600,000 in EBITDA
  • Levitee plans to integrate the Earth Circle Organics brands with its MONKE Nutraceuticals products to leverage supply chain and distribution synergies and accelerate growth by increasing ad spend and inventory levels

Levitee Labs Inc. (CSE: LVT) (the " Company " or " Levitee "), an integrative wellness company with a diversified portfolio of healthcare and wellness assets, is pleased to announce that it has completed the acquisition of all the issued and outstanding shares of Earth Circle Organics Chain Inc. (" Earth Circle Organics ") as of August 3, 2021.

Headquartered in Las Vegas, Nevada, Earth Circle Organics is a direct-to-consumer (DTC) and wholesaler of supplements and superfood products. Earth Circle Organics sells it products primarily in the United States, but it also has a presence in Canada. Earth Circle Organics sells a robust portfolio of organic products, including Ayurvedics, nuts, seeds, berries, coconut oil, premium Himalayan pink salt, chlorella powder, fulvic acid, Nori seaweed, and much more, through multiple distribution channels. Many Earth Circle Organics products sold on Amazon.com consistently are rated 4.5-5.0 stars across thousands of aggregate consumer ratings.

With more than 180 SKUs across three brands ( Earth Circle Organics , Earth Shift Products and Ojio ), Earth Circle Organics has achieved over USD $2.0M in revenue in the past 12 months, with approximately USD $600,000 in EBITDA. 1

Levitee plans to integrate the Earth Circle Organics brands with the Company's MONKE Nutraceuticals products to leverage supply chain and distribution synergies and accelerate growth by increasing ad spend and inventory levels. Levitee intends to finalize new distribution agreements that will place all the brands in additional brick-and-mortar retail stores across the U.S. and Canada.

"We are very pleased to close the acquisition of our sixth cash flowing asset. The Earth Circle Organics portfolio of brands fits perfectly into our model as a vertically integrated wellness company with operations and distribution networks throughout North America," commented Pouya Farmand, Chief Executive Officer at Levitee. "Work has already begun in collaboration with the existing Earth Circle Organics management team on transitioning the products under our umbrella and leveraging synergies to implement aggressive growth initiatives in the vertical."

"I'm excited and proud to announce we have been acquired and are now part of the Levitee Labs family. When I first met the team at Levitee what struck me the most was how passionate and knowledgeable they were about our industry, and the calibre of industry experts they have on their team. I know Earth Circle Organics is in good hands. I'm looking forward to seeing the direction and growth they take the brand," commented John Ward, Owner of Earth Circle Organics.

In consideration for the acquisition of Earth Circle Organics, Levitee issued 488,702 shares at a deemed value of CAD $0.51 per share and paid USD $1,675,000 in cash on closing, with an additional USD $125,000 having been previously paid as a deposit. The Company may also be required to pay up to an additional USD $500,000 pursuant to an earn out mechanism based on gross revenue generated by Earth Circle Organics in the six months following closing.

The previous co-owner of Earth Circle Organics, John Ward, has agreed to continue to run the operations of Earth Circle Organics for a period of six months after closing to ensure continuous business operations and a smooth transfer of Earth Circle Organics' business to Levitee.

About Earth Circle Organics Chain

Earth Circle Organics is a direct-to-consumer and wholesaler of supplements and superfood products in North America. Earth Circle Organics has a robust portfolio of organic products, including Ayurvedics, nuts, seeds, berries, coconut oil, premium Himalayan pink salt, chlorella powder, fulvic acid, Nori seaweed, and much more, totaling over 180 SKUs. Earth Circle Organics products can be found at www.earthcircleorganicswholesale.com and www.earthshiftproducts.com.

About Levitee Labs

Levitee Labs is establishing itself as a leader in the integrative wellness space. Through leveraging an M&A regimen that focuses on the centralization of complementary integrative wellness assets, Levitee Labs aims to transform mental health and addiction treatments through the integration of psychedelic medicines and therapies.

Further information about the Company is available on its website at www.leviteelabs.com .

Forward-Looking Statements

This news release contains certain statements that may constitute forward-looking information under applicable securities laws. All statements, other than those of historical fact, which address activities, events, outcomes, results, developments, performance, or achievements that Levitee anticipates or expects may or will occur in the future (in whole or in part) should be considered forward-looking information. Such information may involve, but is not limited to, statements respecting the integration of Earth Circle Organics' products with Levitee's existing portfolio; the expected benefits and synergies created from the acquisition of Earth Circle Organics; expected revenues and financial performance of Earth Circle Organics; the expected growth of Earth Circle Organics and MONKE Nutraceuticals; Levitee's ability to place its products in brick-and-mortar retail stores; the Company's planned acquisitions, and the expected benefits of same; and Levitee's business plans and proposed products. Forward-looking information is based on currently available competitive, financial and economic data and operating plans, strategies or beliefs as of the date of this news release, but involve known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, performance or achievements of Levitee to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information. These risks and uncertainties include, but are not limited to, those identified and reported in the Company's public filings under the Company's SEDAR profile at www.sedar.com . Although the Company believes that the expectations reflected in its forward-looking statements are reasonable, it can give no assurance that any such statements will prove to be correct. Except as required by law, the Company disclaims any intention and assumes no obligation to update or revise any forward-looking statements to reflect actual results, whether as a result of new information, future events, changes in assumptions, changes in factors affecting such forward-looking statements or otherwise. Any and all forward-looking information contained in this press release is expressly qualified by this cautionary statement.

The CSE (operated by CNSX Markets Inc.) has neither approved nor disapproved of the contents of this press release.

For further information about Levitee, please contact:

Levitee Media Contact

media@leviteelabs.com

Levitee Investor and Corporate Communications

ir@leviteelabs.com

1 Earnings before interest, taxes, depreciation, and amortization (" EBITDA ") is a Non-GAAP measure. EBITDA should not be construed as alternatives to net income/loss determined in accordance with International Financial Reporting Standards (" IFRS "). EBITDA does not have any standardized meaning under IFRS and therefore may not be comparable to similar measures presented by other issuers. The Company believes that EBITDA is a meaningful financial metric as it measures cash generated from operations which the Company can use to fund working capital requirements and fund future growth initiatives.


News Provided by GlobeNewswire via QuoteMedia

The Conversation (0)
Levitee Labs

Levitee Labs

Overview

Shifting legal frameworks and regulatory changes have made psychedelic medicine one of the most promising solutions to mental health and addiction treatment in the modern age. Strong demand from therapists and patients for treatments involving psychedelic drugs like psilocybin has pushed the market to new heights, including a projected market size of over US$10.75 billion by 2027.

Globally, the market for functional mushrooms was US$5.8 billion in 2018 and could grow to a CAGR of 8.0 percent by 2024. Early-movers in the space can expect exceptional growth and economic success as the psychedelic space continues to gain traction as an increasingly positive remedy to limited responses to mental health, substance use and chronic pain crises around the world.

Keep reading...Show less

Transforming the Traditional Landscape of Mental Health, Addiction Treatment and Pain Management Treatment Across Multiple Verticals

Dried mushrooms and capsules aligned on a light surface.

Psychedelics Market Update: H1 2025 in Review

The market for psychedelic drugs is emerging as a strategic investment opportunity in healthcare, with forecasts generally placing its value at around US$6.4 billion in 2025.

This burgeoning sector is set for robust, double-digit compound annual growth, significantly driven by North America, which is anticipated to account for approximately 45 to 50 percent of this market.

The first half of 2025 was characterized by clinical advancements and softening policy stances, furthering momentum and contributing to growing market interest.

Keep reading...Show less
Glowing mushrooms with colorful graphs in the background on a dark surface.

US Policy Momentum, Clinical Progress Fueling Psychedelics Market in 2025

When the US Food and Drug Administration (FDA) rejected Lykos Therapeutics’ new drug application for MDMA-assisted therapy last August, the initial disappointment cast a shadow over the psychedelics industry.

However, the sector is seeing a resurgence of optimism in 2025 on the back of various US developments.

“The psychedelic industry in 2025 will likely see significant advancements in clinical applications, particularly in treating PTSD, depression, and addiction, as research continues to validate their therapeutic potential,” Dr. Markus Ploesser, chief innovation officer at Open Mind Health, told Microdose in January.

Keep reading...Show less
AVECHO BIOTECHNOLOGY

Avecho and Sandoz enter Exclusive License and Development Agreement to Commercialise CBD for Insomnia in Australia

Avecho Biotechnology Limited (ASX: AVE) (“Avecho” or the “Company”) today announced it has signed an exclusive ten-year development and licensing agreement with Sandoz Group AG (“Sandoz”) for the commercial rights to Avecho’s Phase III cannabidiol (“CBD”) capsule for insomnia in Australia. Avecho retains the rights to commercialise the product in all other territories, with Sandoz granted a first right of refusal for these markets. Avecho’s CBD capsule aims to be the first pharmaceutical CBD product registered with the Therapeutic Goods Administration (“TGA”) as an over-the-counter medicine, which market forecasts predict could generate sales surpassing US$125M per annum in Australia2.

Keep reading...Show less

Compass Pathways to announce fourth quarter and year-end financial results on February 27th, 2025

Compass management will host a conference call at 8:00 am ET (1:00pm UK)

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Sunlit mushrooms growing on forest floor, backlit to show vibrant gills and earthy texture.

Psychedelics Market Forecast: Top Trends for Psychedelics in 2025

The psychedelics investment landscape enters 2025 on a complex path marked by both progress and setbacks.

While the US Food and Drug Association (FDA) continues to support research into the therapeutic potential of psychedelics, translating promising findings into approved treatments and accessible care is proving challenging.

This is evident in the recent legislative failures in Massachusetts and California, where initiatives aimed at expanding legal access to psychedelics were met with resistance. The FDA's August 2024 rejection of Lykos Therapeutics' midomafetamine for PTSD treatment underscores the rigorous standards required for regulatory approval.

Keep reading...Show less
Emyria Limited

Emyria and UWA in Partnership to Commercialise Novel Serotonin-Releasing Agents for Mental Health and Neurology

Emyria Limited (ASX: EMD) (“Emyria”, or the “Company”) has signed an exclusive licence agreement with UWA, granting worldwide rights to a rapidly growing portfolio of selective serotonin-releasing agents. (See Appendix for Key Commercial Terms). These novel compounds, realised through a UWA–Emyria research partnership launched in 2021,2 include potential next-generation treatments for mental health and neurological conditions such as PTSD and Parkinson’s disease.

Keep reading...Show less

Latest Press Releases

Related News

×